Ryvu Therapeutics SA
WSE:RVU
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Procter & Gamble Co
NYSE:PG
|
Consumer products
|
| US |
|
Bloom Energy Corp
NYSE:BE
|
Electrical Equipment
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Nextera Energy Inc
NYSE:NEE
|
Utilities
|
| US |
|
Travelzoo
NASDAQ:TZOO
|
Media
|
| US |
|
Apple Inc
NASDAQ:AAPL
|
Technology
|
| US |
|
Microsoft Corp
NASDAQ:MSFT
|
Technology
|
| US |
|
Tesla Inc
NASDAQ:TSLA
|
Automobiles
|
| AU |
|
BHP Group Ltd
ASX:BHP
|
Metals & Mining
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
39.7
64.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Procter & Gamble Co
NYSE:PG
|
US |
|
|
Bloom Energy Corp
NYSE:BE
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Nextera Energy Inc
NYSE:NEE
|
US |
|
|
Travelzoo
NASDAQ:TZOO
|
US |
|
|
Apple Inc
NASDAQ:AAPL
|
US |
|
|
Microsoft Corp
NASDAQ:MSFT
|
US |
|
|
Tesla Inc
NASDAQ:TSLA
|
US |
|
|
BHP Group Ltd
ASX:BHP
|
AU |
This alert will be permanently deleted.
Ryvu Therapeutics SA
Total Equity
Ryvu Therapeutics SA
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Total Equity
zł177.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
37%
|
|
|
I
|
Inno-Gene SA
WSE:IGN
|
Total Equity
zł2.8m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
3%
|
CAGR 10-Years
16%
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Total Equity
zł12.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
65%
|
CAGR 10-Years
N/A
|
|
|
S
|
Selvita SA
WSE:SLV
|
Total Equity
zł316.1m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
See Also
What is Ryvu Therapeutics SA's Total Equity?
Total Equity
177.8m
PLN
Based on the financial report for Sep 30, 2024, Ryvu Therapeutics SA's Total Equity amounts to 177.8m PLN.
What is Ryvu Therapeutics SA's Total Equity growth rate?
Total Equity CAGR 10Y
37%
Over the last year, the Total Equity growth was -38%.
You don't have any saved screeners yet
